niacinamide and gdc-0973

niacinamide has been researched along with gdc-0973 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, DJ; Belvin, M; Chan, J; Chen, H; Friedman, LS; Haling, JR; Hatzivassiliou, G; Heald, R; Hewitt, JF; Hoeflich, KP; Ludlam, MJ; Luoh, SM; Malek, S; Merchant, M; Orr, C; Peck, A; Price, S; Song, K; Ultsch, M; Wiesmann, C; Zak, M	1
Kiessling, MK; Rogler, G	1

Reviews

1 review(s) available for niacinamide and gdc-0973

Article	Year
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. Swiss medical weekly, 2015, Volume: 145 Topics: Animals; Azetidines; Benzamides; Benzimidazoles; Diphenylamine; Genes, ras; GTP Phosphohydrolases; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Mutation; Neoplasms; Niacinamide; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Sulfonamides	2015

Article

Year

Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.

Swiss medical weekly, 2015, Volume: 145

Topics: Animals; Azetidines; Benzamides; Benzimidazoles; Diphenylamine; Genes, ras; GTP Phosphohydrolases; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Mutation; Neoplasms; Niacinamide; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Sulfonamides

2015

Other Studies

1 other study(ies) available for niacinamide and gdc-0973

Article	Year
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013, Sep-12, Volume: 501, Issue:7466 Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf	2013

Article

Year

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

Nature, 2013, Sep-12, Volume: 501, Issue:7466

Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf

2013